Bausch Health acquiring certain Synergy Pharmaceuticals assets — 4 insights

Bausch Health plans to boost its gastroenterology arm by acquiring select assets of Synergy Pharmaceuticals.

Here's what you should know:

1. Synergy Pharmaceuticals filed for chapter 11 bankruptcy Dec. 12. Bausch plans to pay approximately $200 million to acquire the assets.

2. Bausch will serve as a "stalking horse" bidder in a court-supervised auction and sale as Synergy sells off its assets. In this process, Bausch agreed to acquire most of Synergy's assets and offer select employees positions within Bausch.

3. Bausch has particular interest in Synergy's Trulance, which compliments Bausch's Xifaxan. Trulance is an irritable bowel syndrome with constipation treatment, while Xifaxan is an irritable bowel syndrome with diarrhea treatment.

4. Bausch Health will also acquire Synergy's pipeline candidate dolcanatide, an ulcerative colitis drug.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast